Our portfolio of sublingual pharmaceutical products is built on the WaferiX platform technology, and includes pipeline products in the late stage of development
Phase 3-ready
Non-opioid with opioid sparing effects
Positive in Phase 2b clinical studies:
By utilising iX Biopharma’s proprietary sublingual technology WaferiX, we have demonstrated in a phase 1 pharmacokinetic study (BUP001) that BnoX facilitates the rapid absorption of buprenorphine (median Tmax 1.0 hour) with greater absolute bioavailability of 45%. These results suggest superior pharmacokinetics to currently marketed sublingual buprenorphine formulations.
LEARN MORESildenafil citrate has been shown to be a hallmark drug for the treatment of erectile dysfunction in males. Utilising WaferiX, Wafesil is a sildenafil wafer that is administered sublingually. Wafesil comes in a new dosage form and route of administration for patients who cannot or prefer not to swallow. Wafesil is approved for marketing in Australia, outlicensed for China market.
Silcap is a novel small sildenafil capsule that is easy to swallow. Silcap is approved for marketing in Australia and Singapore.